All In Biotech

Drug Trial Radar · NCT07295847

A Study of AZD0120 in Autoimmune Diseases

A Phase 1b/2, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Jan 9, 2026

Primary completion

Feb 22, 2028

Study completion Feb 22, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Conditions

  • Systemic Sclerosis
  • Idiopathic Inflammatory Myopathies
  • Rheumatoid Arthritis

Interventions

  • AZD0120Biological

    CD19/BCMA Autologous CAR T-cell therapy product

  • SOCDrug

    SOC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)Time frame: 1 year
  2. Proportion of Participants Achieving a Revised-CRISS ResponseTime frame: Baseline, Week 52
  3. Proportion of participants achieving TIS response and low corticosteroid doseTime frame: Baseline, Week 52
  4. Proportion of participants achieving Disease Activity Score 28 C reactive protein (DAS28-CRP) < 2.6Time frame: Baseline, Week 12

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona · Not yet recruiting

  • Research Site

    Duarte, California · Not yet recruiting

  • Research Site

    Stanford, California · Not yet recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Chapel Hill, North Carolina · Recruiting

  • Research Site

    Seattle, Washington · Not yet recruiting

  • Research Site

    Clayton, Australia · Not yet recruiting

  • Research Site

    Darlinghurst, Australia · Recruiting

  • Research Site

    Waratah, Australia · Not yet recruiting

  • Research Site

    Berlin, Germany · Not yet recruiting

  • Research Site

    Erlangen, Germany · Not yet recruiting

  • Research Site

    Hamburg, Germany · Not yet recruiting

  • Research Site

    Jena, Germany · Not yet recruiting

  • Research Site

    Mainz, Germany · Not yet recruiting

  • Research Site

    Würzburg, Germany · Not yet recruiting

  • Research Site

    Barcelona, Spain · Not yet recruiting

  • Research Site

    Madrid, Spain · Not yet recruiting

  • Research Site

    Madrid, Spain · Not yet recruiting

  • Research Site

    Huddinge, Sweden · Not yet recruiting

  • Research Site

    Edinburgh, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.